Queen Mary Innovation

Queen Mary Innovation Ltd (QMI) is the technology transfer and commercialisation company of Queen Mary University of London, based in London, United Kingdom. Its stated mission is to protect and license intellectual property and to build sustainable spinout companies and social ventures that turn academic research into real-world impact. QMI works closely with Queen Mary academics across science, medicine, dentistry, engineering and the humanities, helping them understand the market for their ideas, license technologies to innovative companies, and find talented CEOs to lead spinout companies toward future growth. Returns from commercialisation are shared with academic creators and reinvested into future research and translation. QMI's activities span traditional spinouts and an emerging field it calls SHAPE commercialisation — Social Sciences, Humanities and the Arts for People and the Economy — which draws on humanities and social science research to address societal challenges such as climate breakdown and future healthcare models. The company also supports new activity to grow social ventures at Queen Mary. QMI's featured spinouts and portfolio companies include Procyon (biomarker technologies for early cancer detection), ReFleks (a regenerative therapy for joint damage and osteoarthritis), EcoBarrier (a superhydrophobic coating for food and drinks packaging), elcella (a nutrient-based appetite suppressant), Nilocas (a medical device for detecting Coronary Artery Disease), RoEx (AI for music production and recording), AeroSolar (improved manufacturing of perovskite solar panels), Ultima Forma (advanced forming technology), LANDR (AI-powered music mastering and distribution) and hVIVO (human challenge studies for infectious and respiratory products). Its pipeline highlights include methods for predicting patient response to arthritis treatment, a patient-specific digital twin of the aorta (TAVR-AID) and work on predicting pre-eclampsia. QMI is led by CEO Dr Phil Clare, supported by a commercialisation team with experience across research and business, and governed by a board chaired by Dr Tony Raven, former CEO of Cambridge Enterprise. The organisation connects businesses and investors with innovation opportunities arising from Queen Mary's research base, which the university describes as 92% internationally excellent or world-leading.

Queen Mary Innovation Ltd (QMI) is the technology transfer company of Queen Mary University of London, based in London, United Kingdom. It commercialises innovations emerging from the university, working closely with Queen Mary academics to build their innovations into successful businesses or social ventures, or to license them to innovative companies that can take the technology forwards. QMI states that this work is driven by the belief that commercial tools are among the best ways to turn leading research into real-world impact, whether in science, medicine, dentistry, engineering or the humanities. QMI's role spans the full commercialisation pathway: it connects businesses and investors with innovation opportunities, coaches researchers in how to understand the market for their ideas, and finds talented CEOs who can lead spinout companies on to future growth. Returns are shared with academic creators and reinvested into future research and translation, helping to create the next generation of entrepreneurs. Alongside traditional spinouts, QMI supports new activity to grow social ventures at Queen Mary. It has highlighted SHAPE (Social Sciences, Humanities and the Arts for People and the Economy) commercialisation as an emerging field focused on drawing on humanities and social science research to tackle major societal challenges, from climate breakdown to developing healthcare models of the future. QMI's portfolio and featured spinouts include Procyon (biomarker technologies for early cancer detection), ReFleks (a regenerative therapy to repair joint damage, treat osteoarthritis and provide lasting pain relief), EcoBarrier (a superhydrophobic coating for food and drinks packaging), elcella (a nutrient-based appetite suppressant based on a decade of scientific research), Nilocas (a medical device to revolutionise detection of Coronary Artery Disease), RoEx (using AI to transform how musicians produce and record new music), AeroSolar (a new method to improve manufacturing of perovskite solar panels), Ultima Forma (advanced forming technology), LANDR (AI-powered music mastering, distribution, plugins, collaboration, promotion and sample packs) and hVIVO (human challenge studies to test infectious and respiratory products). Pipeline highlights include a method for predicting patient response to arthritis treatment using deep molecular phenotyping and machine learning on a small joint biopsy, TAVR-AID (a patient-specific digital twin of the aorta that simulates blood flow and makes predictions using artificial intelligence) and work on predicting pre-eclampsia. QMI is led by CEO Dr Phil Clare, with a commercialisation team drawn from both research and business backgrounds. The board is chaired by Dr Tony Raven, previously CEO of Cambridge Enterprise at the University of Cambridge, where seed investment grew 730%, spinout creation rose 250% and the university created four unicorn companies. Other directors include Alastair Kilgour, co-founder of Parkwalk Advisors, a venture capital firm described as Britain's most active backer of university spinouts, alongside academic and industry directors. Queen Mary describes its research base as globally significant, with 92% of its research rated internationally excellent or world-leading.

The commercialisation and technology transfer arm of Queen Mary University of London, turning academic research into licensed technologies, spinout companies and social ventures.

• Procyon

  Biomarker technologies for early cancer detection.

• ReFleks

  A pioneering regenerative therapy to repair joint damage, treat osteoarthritis, and provide lasting pain relief.

• EcoBarrier

  A superhydrophobic coating for use in food and drinks packaging which is far superior to conventional waterproofing.

• elcella

  A unique nutrient-based appetite suppressant which releases the body's natural ability to control eating, based on a decade of scientific research.

• Nilocas

  Developing a medical device to revolutionise the detection of Coronary Artery Disease.

• RoEx

  Using AI to transform how musicians of all skill levels produce and record new music.

• AeroSolar

  A new method to improve manufacturing of perovskite solar panels.

• Ultima Forma

  Extending the limits of product performance with advanced forming technology.

• LANDR

  AI-powered music mastering, distribution, plugins, collaboration, promotion and sample packs.

• hVIVO

  The world leader in human challenge studies to test infectious and respiratory products.

• TAVR-AID

  A digital twin of the aorta specific to each patient, which simulates blood flow and makes predictions using artificial intelligence.

1. 1Queen Mary Innovation | A Technology Transfer Companyqminnovation.co.uk
2. 2About us - Queen Mary Innovationqminnovation.co.uk
3. 3Careers - Queen Mary Innovationqminnovation.co.uk
4. 4Our team - Queen Mary Innovationqminnovation.co.uk
5. 5Queen Mary Innovation (United Kingdom) - Wikidatawikidata.org